Detection of Chemotherapy Induced Cardiotoxicity

George Washington University36 enrolled

Overview

To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).

To identify patients at risk of development of heart damage after receiving chemotherapy by obtaining the genetic profile of those who show: elevation of troponin, left ventricular systolic and diastolic dysfunction, and pro-oxidant stress markers.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * undergoing anthracycline and/or trastuzumab therapy for the first time Exclusion Criteria: * abnormal ventricular ejection fraction * past history of, or active cardiac disease including: MI, CHF, angina, arrhythmia requiring medication, valvular disease, uncontrolled systemic hypertension

Locations (1)

George Washington University

Washington D.C., District of Columbia, United States

Outcomes

Primary Outcomes

The genetic profile of patients with anthracycline-induced elevation of troponin-I

Time frame: one year

Secondary Outcomes

Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction

Time frame: one year

Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.